- Home
- WLY vs BLTE Comparison
WLY vs BLTE Comparison
Compare WLY & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLY
- BLTE
- Stock Information
- Founded
- WLY 1807
- BLTE 2018
- Country
- WLY United States
- BLTE United States
- Employees
- WLY N/A
- BLTE N/A
- Industry
- WLY Books
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- WLY Consumer Discretionary
- BLTE Health Care
- Exchange
- WLY Nasdaq
- BLTE Nasdaq
- Market Cap
- WLY 2.2B
- BLTE 2.1B
- IPO Year
- WLY N/A
- BLTE 2022
- Fundamental
- Price
- WLY $36.86
- BLTE $78.06
- Analyst Decision
- WLY
- BLTE Strong Buy
- Analyst Count
- WLY 0
- BLTE 4
- Target Price
- WLY N/A
- BLTE $96.00
- AVG Volume (30 Days)
- WLY 333.0K
- BLTE 66.8K
- Earning Date
- WLY 09-04-2025
- BLTE 11-11-2025
- Dividend Yield
- WLY 3.86%
- BLTE N/A
- EPS Growth
- WLY N/A
- BLTE N/A
- EPS
- WLY 1.78
- BLTE N/A
- Revenue
- WLY $1,670,600,000.00
- BLTE N/A
- Revenue This Year
- WLY $1.45
- BLTE N/A
- Revenue Next Year
- WLY $2.70
- BLTE N/A
- P/E Ratio
- WLY $20.66
- BLTE N/A
- Revenue Growth
- WLY N/A
- BLTE N/A
- 52 Week Low
- WLY $36.10
- BLTE $49.00
- 52 Week High
- WLY $53.96
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- WLY 37.86
- BLTE N/A
- Support Level
- WLY $37.93
- BLTE N/A
- Resistance Level
- WLY $40.90
- BLTE N/A
- Average True Range (ATR)
- WLY 0.81
- BLTE 0.00
- MACD
- WLY -0.26
- BLTE 0.00
- Stochastic Oscillator
- WLY 8.82
- BLTE 0.00
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.